|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 197.40 DKK | +1.44% |
|
+0.87% | +3.43% |
| Mar. 27 | Bavarian Nordic Seeks Expanded Indication for Mpox, Smallpox Vaccine in Europe | MT |
| Mar. 27 | Bavarian Nordic seeks to expand smallpox vaccine use to children | FW |
Business description: Bavarian Nordic A/S
Net sales by revenue source are divided between sales of products (97,2%) and services (2,8%).
Net sales are distributed geographically as follows: the United States (43.2%), Germany (18.6%), France (11.6%), Canada (3.6%), THE United Kingdom (3.4%), Finland (2.9%), Singapore (2.2%), Switzerland (1.7%), Australia (1.3%), Saudi Arabia (1.2%), Spain (0.6%), and others (9.7%).
Number of employees: 1,692
Sales by Activity: Bavarian Nordic A/S
| Fiscal Period: December | 2021 (DKK) | 2022 (DKK) | 2023 (DKK) | 2024 (DKK) | 2025 (DKK) |
|---|---|---|---|---|---|
Biotechnology | 1.9B | 3.15B | 7.06B | 5.72B | 6.24B |
Geographical breakdown of sales: Bavarian Nordic A/S
| Fiscal Period: December | 2021 (DKK) | 2022 (DKK) | 2023 (DKK) | 2024 (DKK) | 2025 (DKK) |
|---|---|---|---|---|---|
USA | 1.07B | 842M | 2.58B | 2.7B | 2.7B |
Germany | 258M | 650M | 714M | 973M | 1.16B |
France | - | 268M | 740M | 269M | 724M |
Other Geographic Markets | 103M | 304M | 345M | 359M | 519M |
Canada | - | 197M | 1.56B | 493M | 223M |
England | - | - | - | - | 214M |
Finland | - | - | - | 98.47M | 183M |
Singapore | - | - | - | 125M | 138M |
Switzerland | 24.14M | 70.99M | 108M | 52.59M | 108M |
Australia | - | 97.66M | 338M | - | 80.31M |
Saudi Arabia | - | 100M | 4.84M | 266M | 72.6M |
Spain | - | - | 430M | - | 35.36M |
Italy | - | - | - | - | 35.02M |
Japan | 24.11M | - | - | - | 29.58M |
Austria | 28.04M | - | - | - | 25.31M |
Netherlands | - | - | - | 69.79M | - |
Taiwan | - | - | 53.8M | 40.05M | - |
Chile | - | - | 65.19M | - | - |
Hong Kong | - | 116M | 13.94M | - | - |
Belgium | 264M | 335M | - | 218M | - |
United Kingdom | 16.98M | 169M | 44.72M | - | - |
Sweden | 33.48M | - | 71.97M | 49.8M | - |
The Netherlands | 78.17M | - | - | - | - |
Executive Committee: Bavarian Nordic A/S
| Manager | Title | Age | Since |
|---|---|---|---|
Paul Chaplin
CEO | Chief Executive Officer | 59 | 2014-05-27 |
Henrik Juuel
DFI | Director of Finance/CFO | 61 | 2018-10-31 |
Russell Thirsk
COO | Chief Operating Officer | 58 | 2022-03-31 |
| Investor Relations Contact | - | - | |
| Corporate Officer/Principal | 59 | - |
Composition of the Board of Directors: Bavarian Nordic A/S
| Director | Title | Age | Since |
|---|---|---|---|
Frank Verwiel
BRD | Director/Board Member | 63 | 2016-04-19 |
Anne Eberhard
CHM | Chairman | 63 | 2025-11-12 |
Anja Gjøl
BRD | Director/Board Member | 46 | 2020-12-31 |
Heidi Hunter
BRD | Director/Board Member | 67 | 2022-12-31 |
| Director/Board Member | 59 | 2022-12-31 | |
Montse Montaner
BRD | Director/Board Member | 58 | 2024-04-15 |
| Director/Board Member | 51 | 2025-04-08 |
Holdings: Bavarian Nordic A/S
| Name | Equities | % | Valuation |
|---|---|---|---|
BAVARIAN NORDIC A/S 1.32% | 1,047,740 | 1.32% | 33 M $ |
Company details: Bavarian Nordic A/S
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.44% | +0.87% | +35.34% | -2.61% | 2.39B | |
| -1.65% | +0.42% | +28.27% | +158.07% | 841B | |
| -1.18% | -1.88% | +57.16% | +45.16% | 574B | |
| -2.10% | -0.43% | +18.79% | +28.85% | 368B | |
| -0.09% | 0.00% | +30.43% | +16.21% | 320B | |
| -0.30% | -0.56% | +52.18% | +30.95% | 318B | |
| -1.03% | +0.46% | +53.35% | +7.94% | 300B | |
| -0.34% | -1.17% | +41.43% | +40.20% | 295B | |
| -1.29% | +0.89% | +22.74% | +39.61% | 189B | |
| -2.18% | -0.52% | +34.12% | +68.39% | 173B | |
| Average | -0.87% | +0.34% | +37.38% | +43.28% | 338.03B | |
| Weighted average by Cap. | -1.18% | +0.00% | +37.97% | +64.49% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BAVA Stock
- Company Bavarian Nordic A/S
Select your edition
All financial news and data tailored to specific country editions
